# A Single-arm Evaluation of the Effect of HCV Treatment on Cardiovascular Disease Risk

> **NCT03585101** · PHASE4 · WITHDRAWN · sponsor: **University of California, Los Angeles**

## Conditions studied

- Hepatitis C

## Interventions

- **DRUG:** Elbasvir/grazoprevir

## Key facts

- **NCT ID:** NCT03585101
- **Lead sponsor:** University of California, Los Angeles
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-08
- **Primary completion:** 2019-06
- **Final completion:** 2020-04
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Funding no longer available
- **Last updated:** 2018-08-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03585101

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03585101, "A Single-arm Evaluation of the Effect of HCV Treatment on Cardiovascular Disease Risk". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT03585101. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*